.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Covington
McKesson
Julphar
Teva
Farmers Insurance
Colorcon
Mallinckrodt
Cipla
Daiichi Sankyo

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,791,154

« Back to Dashboard

Which drugs does patent 8,791,154 protect, and when does it expire?


Patent 8,791,154 protects PAZEO and is included in one NDA. There has been one Paragraph IV challenge on Pazeo.

This patent has twenty-five patent family members in seventeen countries.

Summary for Patent: 8,791,154

Title:High concentration olopatadine ophthalmic composition
Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
Inventor(s): Gamache; Daniel A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Galan; Francisco Javier (Barcelona, ES), Perdiguer; N ria Carreras (Barcelona, ES), Singh; Onkar N. (Arlington, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/475,607
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
PAZEO
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC206276-001Jan 30, 2015RXYesYes► Subscribe► SubscribeY TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,791,154

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,533,053High concentration olopatadine ophthalmic composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,791,154

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina086490► Subscribe
Australia2012255046► Subscribe
Canada2826725► Subscribe
China103458894► Subscribe
China105534970► Subscribe
Colombia6801738► Subscribe
European Patent Office2709610► Subscribe
European Patent Office3045172► Subscribe
Spain2587869► Subscribe
Hong Kong1194971► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Chubb
Mallinckrodt
Colorcon
Federal Trade Commission
Chinese Patent Office
Johnson and Johnson
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot